Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 376 - 400 of 1981 in total
Levocetirizine is a selective histamine H1 antagonist used to treat a variety of allergic symptoms.[A181748,A181790,L7694] It is the R enantiomer of cetirizine. Levocetirizine has greater affinity for the histamine H1 receptor than cetirizine. Levocetirizine was granted FDA approval in 1995.
Approved
Matched Salts cas: … 130018-87-0
Matched Mixtures name: … LEVMONT 2.5/4 MG CIGNEME TABLET, 90 ADET ... LEVMONT 2.5/4 MG TOZ İÇEREN SAŞE, 90 ADET ... LEPIXOS 5 MG/10 MG FILM TABLET ,90 ADET …
Matched Products: … LEVOKAST 5 MG/10 MG FILM KAPLI TABLET, 90 ADET …
Ulipristal is a selective progesterone receptor modulator used for the purposes of emergency contraception (Ella) and for the treatment of uterine fibroids (Fibristal). It is a derivative of 19-norprogesterone and has both antagonistic and partial agonist activity at the progesterone receptor. It also binds to glucocorticoid receptor, however compared to...
Approved
Matched Iupac: … 11S,14R,15S,17R)-14-acetyl-17-[4-(dimethylamino)phenyl]-14-hydroxy-15-methyltetracyclo[8.7.0.0^{2,7}.0^ …
Aripiprazole is an atypical antipsychotic orally indicated for the treatment of schizophrenia, bipolar I, major depressive disorder, irritability associated with autism, and Tourette's. It is also indicated as an injection for agitation associated with schizophrenia or bipolar mania. Aripiprazole exerts its effects through agonism of dopaminergic and 5-HT1A receptors and...
Approved
Investigational
Matched Products: … IGNIS 10 MG TABLET, 90 ADET ... IGNIS 15 MG TABLET, 90 ADET ... IGNIS 30 MG TABLET, 90 ADET …
Doxazosin is an alpha-1 antagonist used for the treatment of benign prostatic hypertrophy (BPH) symptoms and hypertension. Other members of this drug class include Prazosin, Terazosin, Tamsulosin, and Alfuzosin. Because of its long-lasting effects, doxazosin can be administered once a day. It is marketed by Pfizer and was initially approved...
Approved
Matched Products: … CARDURA 2 MG TABLET, 90 ADET ... CARDURA 4 MG TABLET, 90 ADET …
Ethiodized oil is used by injection as a radio-opaque contrast agent. The composition of the oil is comprised of iodine combined with ethyl esters of fatty acids of poppyseed oil. And although these esters are primarily as ethyl monoiodostearate and ethyl diiodostearate, the actual, specific structure is unknown.
Approved
Investigational
Atosiban is an inhibitor of the hormones oxytocin and vasopressin. It is used intravenously to halt premature labor. Although initial studies suggested it could be used as a nasal spray and hence would not require hospital admission, it is not used in that form. Atobisan was developed by the Swedish...
Approved
Investigational
Duchenne muscular dystrophy (DMD) is an X-linked recessive allelic disorder characterized by a lack of functional dystrophin protein, which leads to progressive impairment of ambulatory, pulmonary, and cardiac function and is invariably fatal. A related, albeit a less severe, form of muscular dystrophy known as Becker muscular dystrophy (BMD) is...
Approved
Investigational
Colfosceril palmitate is a synthetic pulmonary surfactant administered in infants with respiratory distress syndrome. It was part of the first generation of commercially available artificial surfactants. It was developed by Burroughs Wellcome and it was FDA approved on August 6, 1990. Nowadays colfosceril palmitate is under the state of canceled...
Approved
Investigational
Withdrawn
Murine IgG2a lambda monoclonal antibody against CD20 antigen (2 heavy chains of 451 residues, 2 lambda chains of 220 residues). It is produced in an antibiotic-free culture of mammalian cells. It can be covalently linked to Iodine 131 (a radioactive isotope of iodine).
Approved
Investigational
Bazedoxifene is a third generation selective estrogen receptor modulator (SERM), developed by Pfizer following the completion of their takeover of Wyeth Pharmaceuticals. In late 2013, Pfizer received approval for bazedoxifene as part of the combination drug DUAVEE in the prevention (not treatment) of postmenopausal osteoporosis. It is approved in the...
Approved
Investigational
Matched Description: … In late 2013, Pfizer received approval for bazedoxifene as part of the combination drug DUAVEE in the ... In 2013, the combination product containing conjugated estrogens and bazedoxifene was approved by the …
An antibiotic first isolated from cultures of Streptomyces venezuelae in 1947 but now produced synthetically. It has a relatively simple structure and was the first broad-spectrum antibiotic to be discovered. It acts by interfering with bacterial protein synthesis and is mainly bacteriostatic. (From Martindale, The Extra Pharmacopoeia, 29th ed, p106)...
Approved
Vet approved
Withdrawn
Teniposide is a semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Teniposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent cells from entering into the mitotic...
Approved
Matched Iupac: … 3,2-d][1,3]dioxin-6-yl]oxy}-10-(4-hydroxy-3,5-dimethoxyphenyl)-4,6,13-trioxatetracyclo[7.7.0.0^{3,7}.0^ …
Ospemifene is a new selective non-hormonal estrogen receptor modulator (SERM) that is used for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause. FDA approved on February 26, 2013.
Approved
Investigational
Matched Description: … FDA approved on February 26, 2013. …
Yellow fever vaccine prevents against Yellow Fever, a viral hemorrhagic disease caused by the transmission of a flavivirus through the bite of an infected mosquito. Symptoms of Yellow fever can range from asymptomatic, to mild flu-like illness, to more severe symptoms such as shock, jaundice, internal bleeding, and organ failure...
Approved
Investigational
Matched Description: … developing within 10 days after vaccination; in two separate clinical trials of Yellow Fever Vaccine, 90% …
Rasagiline is an irreversible inhibitor of monoamine oxidase and is used as a monotherapy in early Parkinson's disease or as an adjunct therapy in more advanced cases.
Approved
Matched Products: … RASALAS 1 MG TABLET, 90 ADET …
Panitumumab (ABX-EGF) is a recombinant human IgG2 monoclonal antibody that binds specifically to the human epidermal growth factor receptor (EGFR). This drug is an antineoplastic agent. Panitumumab was granted FDA approval on 27 September 2006.
Approved
Investigational
Trametinib is an orally bioavailable mitogen-activated extracellular signal-regulated kinase 1 (MEK1) and MEK2 inhibitor.[A258298,A258293] It was first approved by the FDA in May 2013 for the treatment of melanoma. It was later approved by Health Canada on July 18, 2013 and by the European Commission on June 30, 2014. Trametinib...
Approved
Matched Description: … [A258298,A258293] It was first approved by the FDA in May 2013 for the treatment of melanoma. ... [A258298] It was later approved by Health Canada on July 18, 2013 [L45588] and by the European Commission …
Luliconazole is a topical antifungal agent that acts by unknown mechanisms but is postulated to involve altering the synthesis of fungi cell membranes. It was approved by the FDA (USA) in November 2013 and is marketed under the brand name Luzu. Luliconazole is also approved in Japan.
Approved
Matched Description: … It was approved by the FDA (USA) in November 2013 and is marketed under the brand name Luzu. …
Candesartan is an angiotensin-receptor blocker (ARB) that may be used alone or with other agents to treat hypertension. It is administered orally as the prodrug, candesartan cilexetil, which is rapidly converted to its active metabolite, candesartan, during absorption in the gastrointestinal tract. Candesartan lowers blood pressure by antagonizing the renin-angiotensin-aldosterone...
Approved
Matched Mixtures name: … AYRA PLUS 16/12,5 MG TABLET, 90 ADET …
Matched Products: … AYRA 8 MG TABLET, 90 ADET ... AYRA 16 MG TABLET, 90 ADET …
Nateglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Nateglinide is an amino acid derivative that induces an early insulin...
Approved
Investigational
Matched Mixtures name: … NATMET 120/1000 MG TEDAVI PAKETI, 90+90 ADET ... NATMET 120/500 MG TEDAVI PAKETI, 90+90 ADET ... NATMET 120/850 MG TEDAVI PAKETI, 90+90 ADET …
Escitalopram is a selective serotonin re-uptake inhibitor (SSRI) and the S-enantiomer of racemic citalopram. It is used to restore serotonergic function in the treatment of depression and anxiety.[L8513,L8516,L8522] Escitalopram is approximately 150 times more potent than citalopram’s R-enantiomer and is responsible for the vast majority of citalopram’s clinical activity, with...
Approved
Matched Products: … ESLONG 10 MG EFERVESAN TABLET, 90 ADET ... ESLONG 15 MG EFERVESAN TABLET, 90 ADET ... ESLONG 20 MG EFERVESAN TABLET, 90 ADET …
Dasiglucagon is a glucagon analog that acts to increase blood sugar levels. It consists of 29 amino acids similar to endogenous glucagon; however, it contains seven substituted amino acids for improved physical and chemical stability in its drug formulation. In March 2021, the FDA approved dasiglucagon to treat severe hypoglycemia...
Approved
Investigational
Magnesium chloride salts are highly soluble in water and the hydrated form of magnesium chloride can be extracted from brine or sea water.
Approved
Matched Mixtures name: … CONCENTRADO HC 13-90 ... Prismasol 0 ... Prismasol Bgk2/0
Ritlecitinib (PF-06651600) is a highly selective inhibitor of Janus kinase 3 (JAK3) and the tyrosine kinase expressed in hepatocellular carcinoma (TEC) kinase family. In June 2023, it was approved by the FDA for the treatment of severe alopecia areata in adults and adolescents 12 years and older.[L47092,L47127] It was further...
Approved
Investigational
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare acquired hematologic disease characterized by hemolysis, thrombophilia, and bone marrow dysfunction.[A263501,L50417] Both hemolysis and thrombophilia are mediated primarily by the complement system. Standard therapy for PNH involves the use of complement C5 inhibitors (e.g. eculizumab, ravulizumab) which are effective in mitigating complement-mediated intravascular...
Approved
Investigational
Displaying drugs 376 - 400 of 1981 in total